^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    EXS21546

    i
    Other names: EXS21546, EVOEXS 21546 , EVOEXS21546 , EXS-21546
    Associations

    News

    Trials
    Company:
    Evotec, Exscientia
    Drug class:
    Adenosine A2A receptor antagonist
    Related drugs:
    Associations

    News

    Trials
    12ms
    Study to Assess EXS21546 in Combination in Patients With Advanced Solid Tumours (clinicaltrials.gov)
    P1b/2a, N=6, Terminated, Exscientia AI Limited | N=110 --> 6 | Trial completion date: Mar 2026 --> Oct 2023 | Recruiting --> Terminated | Trial primary completion date: Sep 2025 --> Sep 2023; Emerging data demonstrates challenge for EXS21546 to reach suitable therapeutic index.
    Enrollment change • Trial completion date • Trial termination • Trial primary completion date • Combination therapy • Metastases
    |
    EXS21546
    over1year
    Data from first-in-human study of EXS21546, an A2A receptor antagonist, now progressing into phase 1 in RCC/NSCLC (AACR 2023)
    Safety and tolerability of our A2AR antagonist EXS21546 were confirmed in a HV study, allowing selection of a starting dose for the ongoing IGNITE Phase 1/2 study. IGNITE trial design was based on extensive simulations to enable the most efficient continuous reassessment method settings, and will allow further verification of the patient enrichment biomarker strategy.
    P1 data • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • ADORA2A (Adenosine A2a Receptor)
    |
    CD8 positive
    |
    EXS21546